Navigation Links
Therapeutic potential of embryonic stem cells

Are stem cells ready for prime time?

The therapeutic potential of embryonic stem cells has been an intense focus of study and discussion in biomedical research and has resulted in technologies to produce human induced pluripotent stem cells (hiPSCs). Derived by epigenetic reprogramming of human fibroblasts, these hiPSCs are thought to be almost identical to human embryonic stem cells (hESCs) and provide great promise for patient-tailored regenerative medicine therapies. However, recent studies have suggested noteworthy differences between these two stem cell types which require additional comparative analyses.

Scientists at Children's Memorial Research Center at Northwestern University Feinberg School of Medicine investigated the expression of key members of the Nodal embryonic signaling pathway, critical to maintaining pluripotency, in hiPSC and hESC cell lines. Nodal is an important morphogen a soluble molecule that can regulate cell fate in embryological systems that requires tight regulatory control of its biological function.

The group's results demonstrated slightly lower levels of Nodal and Cripto-1 (Nodal's co-receptor) and a dramatic decrease in Lefty (Nodal's inhibitory regulator) in hiPSCs compared with hESCs, suggesting less regulatory control of cell fate in reprogrammed stem cells. Based on these findings, additional work addressed the implications associated with the epigenetic reprogramming of hiPSCs and examined a global comparative analysis of 365 microRNAs (miRs) in hiPSC vs. hESC lines.

The data revealed 10 highly expressed miRs in hiPSCs with greater than 10-fold difference, which have been shown to be cancer related. Collectively, these data demonstrate cancer hallmarks expressed by hiPSCs, which will require further elucidation for their impact on clinical applications, especially with respect to the fate of precancerous stem cells.


Contact: Peggy Jones
Children's Memorial Hospital

Page: 1

Related medicine news :

1. Osseon Therapeutics, Inc. Announces it has Received Canadian Medical Device Licenses From Health Canada
2. Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
3. Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
4. Reportlinker Adds The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
5. Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan
6. Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
7. SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea
8. Cell Therapeutics, Inc. (CTI) Piper Jaffray Presentation to be Webcast
9. The therapeutic benefits of the human-animal bond
10. Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions
11. Echo Therapeutics Provides Business Update
Post Your Comments:
(Date:12/1/2015)... ... 02, 2015 , ... Ruth Pearson was struggling. She had been laid off ... assistance and quickly losing hope of recovering her former life, Pearson was desperate for ... attending a women’s retreat when she experienced a particularly impactful worship service. Without help ...
(Date:12/1/2015)... ... December 01, 2015 , ... On Tuesday ... to NASDAQ to educate the personnel on spinal decompression therapy and offer his ... a nonsurgical procedure. The benefits come from creating negative intradiscal pressure which is ...
(Date:12/1/2015)... ... December 01, 2015 , ... Henderson, a ... to receive Gigabit Internet through a partnership this year with Aeneas Internet and ... is an attractive destination for entrepreneurs who want to build a business. Whether ...
(Date:12/1/2015)... ... , ... Florida Hospital Tampa is the first health care provider in the region ... , vBloc® Therapy is a vagal blocking therapy, delivered via the Maestro® System, for the ... (BMI) of at least 40 to 45 kg, or a BMI of at least 35 ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Califia ... today announced that its iconic bottle has won top honors in Beverage World Magazine’s ... The Company also announced that it has been selected as a 2015 U.S.A. Taste ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... --> --> ... by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic ... Analysis - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 40,281.6 Million in 2015, at ... Browse 37 market data T ...
(Date:12/1/2015)... 2015 Assurex Health, Inc. today announced ... healthcare providers an expanded range of options in ... from depression, anxiety, bipolar disorder, posttraumatic stress disorder ... i .   --> ... addition of two new drug classes, 17 FDA-approved ...
(Date:12/1/2015)... , Dec. 1, 2015  Six months of adjunctive metformin ... type 1 diabetes, according to new research from T1D ... it may have a beneficial effect on measures of obesity, ... issue of the Journal of the American Medical Association ... the effect of metformin on overweight and obese adolescents with ...
Breaking Medicine Technology: